High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:480541C85.7
Who is this for?
Show terms as
1FDA treatments1Active trials3Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

High-grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement is an aggressive type of blood cancer that affects a type of white blood cell called a B-cell. This disease is sometimes called 'double-hit' or 'triple-hit' lymphoma, depending on how many gene changes are involved. When two genes are rearranged (most often MYC and BCL2, or MYC and BCL6), it is called double-hit lymphoma. When all three genes are rearranged, it is called triple-hit lymphoma. These names come from the fact that the cancer cells have two or three specific genetic 'hits' or changes that make the cancer grow very fast. This lymphoma usually starts in the lymph nodes — small glands found throughout the body that are part of the immune system — but it can spread quickly to other organs, including the bone marrow, liver, and brain. Because it grows so rapidly, people often notice symptoms within weeks. Common symptoms include swollen lymph nodes (lumps under the skin in the neck, armpits, or groin), extreme tiredness, unexplained weight loss, drenching night sweats, and fever. Some people also experience belly pain or swelling if the lymphoma affects organs in the abdomen. Treatment for this lymphoma is intensive and typically involves combination chemotherapy regimens. Standard treatments like R-CHOP (a combination of rituximab plus four chemotherapy drugs) are often used, though many specialists prefer more intensive regimens such as DA-EPOCH-R. Because this cancer is so aggressive, treatment usually begins very quickly after diagnosis. Research into newer therapies, including CAR-T cell therapy and targeted drugs, is ongoing and offering new hope for patients.

Key symptoms:

Swollen lymph nodes (painless lumps in the neck, armpits, or groin)Extreme tiredness or fatigue that does not improve with restUnexplained weight lossDrenching night sweatsFever without a clear infectionBelly pain, bloating, or a feeling of fullnessShortness of breath or chest discomfortLoss of appetiteBone pain if the cancer has spread to the bone marrowConfusion or neurological symptoms if the brain is affectedFrequent infections due to a weakened immune systemPale skin or easy bruising from low blood counts

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Mar 2018Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Epkinly

epcoritamab-bysp· Genmab US, Inc.■ Boxed WarningAccelerated Approval
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell ly

For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.

Clinical Trials

1 recruitingView all trials with filters →
Phase 21 trial
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Phase 2
Actively Recruiting Prior treatment eligible
PI: Thomas E Witzig, M.D. (Mayo Clinic) · Sites: Mankato, Minnesota; Rochester, Minnesota +2 more · Age: 1899 yrs

Specialists

3 foundView all specialists →
TM
Thomas E Witzig, M.D.
Mankato, Minnesota
Specialist

Rare Disease Specialist

SA
Stephen M Ansell
ROCHESTER, MN
Specialist
PI on 1 active trial5 High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement publications

Treatment Centers

8 centers
⚗️ Trial Site

Mayo Clinic in Rochester

📍 Rochester, Minnesota

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

Travel Grants

No travel grants are currently matched to High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement.

Search all travel grants →NORD Financial Assistance ↗

Community

Open High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangementForum →

No community posts yet. Be the first to share your experience with High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement.

Start the conversation →

Latest news about High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

Disease timeline:

New trial: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron

Phase PHASE2 trial recruiting. Ascorbic Acid

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which genes are rearranged in my lymphoma — is it double-hit or triple-hit — and how does that affect my treatment plan?,Which chemotherapy regimen do you recommend for me, and why — DA-EPOCH-R or R-CHOP or something else?,Will I need treatment to protect my brain from the cancer, and what does that involve?,What are the chances that my cancer will respond to treatment, and what happens if it comes back?,Am I a candidate for a stem cell transplant or CAR-T cell therapy, either now or in the future?,Are there any clinical trials I should consider?,What support services — such as social work, mental health counseling, or financial assistance — are available to me and my family?

Common questions about High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

What is High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement?

High-grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement is an aggressive type of blood cancer that affects a type of white blood cell called a B-cell. This disease is sometimes called 'double-hit' or 'triple-hit' lymphoma, depending on how many gene changes are involved. When two genes are rearranged (most often MYC and BCL2, or MYC and BCL6), it is called double-hit lymphoma. When all three genes are rearranged, it is called triple-hit lymphoma. These names come from the fact that the cancer cells have two or three specific genetic 'hits' or changes that make the cancer grow

How is High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement inherited?

High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement typically begin?

Typical onset of High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement is adult. Age of onset can vary across affected individuals.

Are there clinical trials for High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement?

Yes — 1 recruiting clinical trial is currently listed for High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement?

3 specialists and care centers treating High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.